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under the CC BY-NC-ND license (http:Abstract Robot-assisted radical cystectomy with intracorporeal urinary diversion (RARC-
ICUD) has only recently been explored as a viable surgical option for patients with
muscle-invasive bladder cancer seeking satisfactory oncologic control while benefiting from
minimally invasive surgical techniques. Inspired by earlier open and laparoscopic work,
initial descriptions of RARC-ICUD were published in 2003, and have since been followed by
multiple larger case series which have suggested promising outcomes for our patients. How-
ever, the rate of adoption has remained relatively slow when compared to other robot-
assisted procedures such as the radical prostatectomy, likely owing to longer operative
times, operative complexity, costs, and uncertainty regarding oncologic efficacy. The oper-
ative technique for RARC-ICUD has evolved over the past decade and several high-volume
centers have shared tips to improve efficiency and make the operation possible for a growing
number of urologists. Though there are still questions regarding economic costs, effective-
ness, and generalizability of outcomes reported in published data, a growing dataset has
brought us ever closer to the answers. Here, we present our current operative technique
for RARC-ICUD and discuss the state of the literature so that the urologist may hold an
informed discussion with his or her patients.
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RARC-ICUD 1571. Introduction
Open radical cystectomy (ORC) with extended pelvic lymph
node dissection and urinary diversion has long been the gold
standard for localized muscle invasive urothelial carcinoma
of the bladder [1]. The growing popularity of laparoscopic
surgery in the early 1990s ultimately allowed for the
development of the first minimally invasive radical cys-
tectomy (RC) with extracorporeal ileal conduit (IC)
reported in 1995 [2]. Early adoption was stimulated by re-
ports of transitioning from ORC to hand-assisted laparo-
scopic radical cystectomy (LRC) to pure LRC with
extracorporeal diversion [3]. Larger series of LRC have since
been published demonstrating comparable outcomes to
ORC, an important stepping-stone in the journey toward
robotic alternatives [4].
The motivation for developing such a technique was
that of minimally invasive surgery in all subspecialties: to
reduce the morbidity of the operation and improve periop-
erative outcomes such as blood loss, hospital stay, and pa-
tient satisfaction [5]. Five years later in 2000, first LRCwith a
completely formed intracoporeal ileal conduit (ICIC) was
reported [6], which was followed with report of orthotopic
neobladder (ONB) in 2002 [7]. Predictably, the advent and
ensuing popularity of the da Vinci Surgical System (Intuitive
Surgical Inc., Sunnyvale, CA, USA) inspired the initial reports
of robotic-assisted radical cystectomy (RARC). RARC with
extracorporeal neobladder formation was first described in
males in 2003 [8], andwas soon followed by a series in female
patients as well [9].
Throughout the past decade, implementation of RARC
with or without intracorporeal urinary diversion (ICUD) has
been primarily limited to high volume academic centers.
Increased operative time, unfamiliarity with the technology
and technique, cost, limited access to quality training ini-
tiatives, and uncertainty regarding oncologic and functional
outcomes have all been cited as possible barriers to early
widespread adoption of the procedure [10e12]. More
recently, however, data have been published supporting
comparable oncologic outcomes to ORC in the setting of
decreased blood loss and shorter length of stay. Random-
ized control trials (RCTs) comparing RARC to ORC have
recently been completed with mixed results, but review of
the available literature demonstrates increasingly larger
prospective series with comparable and sometimes superior
perioperative outcomes and complication rates. This re-
view will summarize our surgical technique for complete
ICUD as well as the current state of the literature, which
suggests a growing number of centers are performing RARC-
ICUD safely and effectively.
2. Operative technique
Following Menon et al.’s original description [8], many
different institutions have published various modifications
for RARC and urinary diversion, including our own. Over the
years, we have continued to make modifications to improve
the efficiency of the procedure, and will report our latest
technique here, which may also be reviewed with figures
and intraoperative images in an upcoming publication [13].Where applicable, we will also comment on variations re-
ported by other institutions so that the reader may consider
the applicability of each of these to his or her own practice.
2.1. Operating room configuration and patient
preparation
Prior to induction of general anesthesia, the patient is given
5000 units heparin for deep vein thrombosis prophylaxis.
After administering general endotracheal anesthesia, an
orogastric tube and Foley catheter are placed. Intravenous
antibiotics appropriate for the coverage of enteric organ-
isms are administered.
The patient is moved into the dorsal lithotomy position,
ensuring adequate padding of all extremities to avoid po-
tential compartment syndrome and/or neuropraxia. We
prefer to tuck the patient’s arms at his or her side. Before
prepping and draping, the patient should be placed into the
steep Trendelenburg position (30e45) to ensure the pat-
ent is properly strapped and stable. The use of shoulder
pads or Velcro straps has both been described. The Tren-
delenburg position is applied to slide the bowel out of the
pelvis and provide adequate exposure during cys-
toprostatectomy. During urinary diversion, Trendelenburg
should be reduced to 15 or less. For this latter portion of
the procedure, the robot may be re-docked between the
patient’s legs while in dorsal lithotomy, or side-docked
after the patient is moved to the supine position. The pa-
tient is prepped and draped in the usual sterile fashion,
similar to robot-assisted radical prostatectomy. A prepa-
ration time-out is performed, and a sterile field is created
by prepping the patient’s penis (vagina in female), peri-
neum and proximal thighs up to the infra-xiphoid abdomen.
2.2. Trocar placement and robotic configuration
We typically perform RARC-ICUD using the da Vinci Xi
Robotic System (Intuitive Surgical Inc.) though it should be
noted that this method can be easily adapted for the S and
Si systems as well. Pneumoperitoneum is obtained using a
Veress needle through a vertical skin incision about 5 cm
above the umbilicus. The abdomen is insufflated to
15 mmHg, and the 8-mm camera port is then inserted in the
midline. With the camera inserted, the peritoneal cavity is
inspected to rule out injury upon entry into the abdomen.
The remaining three robotic ports and two assistant
ports are then placed under direct vision 1e2 cm above the
level of the umbilicus in a transverse line across the
abdomen. The first two robotic ports are placed 10 cm
lateral and slightly inferior to the camera port on either
side. The additional robotic port is placed another 7e10 cm
lateral to the right-sided robotic port and three finger-
breadths superior to the right anterior superior iliac spine
(ASIS). This may or may not be in line with the other robotic
ports. The 12-mm AirSeal (SurgiQuest Inc., Milford, CT,
USA) port is then placed on the left side, 5e7 cm superior to
the ASIS, essentially mirroring the placement of the third
robotic port. Placing the third robotic port on the right and
Airseal on the left is a departure from a previously
described method from our institution in which these
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uration facilitates bowel manipulation by avoiding acute-
angle stapling. The final assistant port should be placed
through the pre-marked stomal site when performing an IC.
We have performed this operation with a 5-mm port in this
position, though an additional 12- or 15-mm port may be
used here to provide additional opportunities for stapling
and specimen collection with a laparoscopic bag. When
performing ONB, left side placement of the assistant port is
advantageous to the assistant, who will be sitting at the
patient’s left. The robot is then docked between the pa-
tient’s legs.
The camera is placed via the port attached to the sec-
ond robotic arm. We typically begin with Hot Shears
monopolar curved scissors (Intuitive Surgical Inc.) in the
right hand (arm 3), fenestrated bipolar forceps (Intuitive
Surgical Inc.) in the left hand (arm 1), and a ProGrasp
forceps (Intuitive Surgical Inc.) in the fourth arm. During
the urinary diversion, two needle drivers are also used,
which may include a Large SutureCut (Intuitive Surgical
Inc.) depending on surgeon preference. The choice of lens
is ultimately dependent on surgeon preference as well. The
majority of the operation is performed with the 0 lens,
though we do advocate for specialized use of the 30 lens
when dissecting deep in the pelvis, for extended lymph
node dissection particularly near the aortic bifurcation,
and at the time of posterior/retro-apical prostatic
dissection.
2.3. Urinary diversion
We have previously described our technique for RARC with
or without ePLND and continue to perform it in a similar
manner [14,15]. After fully dissecting and freely mobilizing
the bladder and prostate, attention is turned to the urinary
diversion. Several different techniques are available to the
urologist, and we will focus our technique for orthotopic
ileal neobladder here. ICIC and more recently, intra-
corporeal continent cutaneous urinary diversion, have also
been described.
2.3.1. Completely intracorporeal ileal neobladder
Following RARC, the robot is undocked and the patient
moved into shallow Trendelenburg (10e15). One advan-
tage of the Xi system is side-docking ability, which allows
the diversion to be performed with the patient in the su-
pine position, thereby decreasing the risk of positioning
complications [16]. Prograsp (Intuitive Surgical, Inc.,
Sunnyvale, California, USA) forceps are used in arm 3 on the
right and fenestrated bipolar forceps are placed in arm 1 on
the left for bowel manipulation. A needle driver may
alternatively be used in one of these arms to save on cost.
Before isolating bowel, we place two separate 3-0 barbed
sutures (V-loc; Covidien, New Haven, CT, USA) at 5- and 7-
o’clock in the urethra, and then bring them through the
anterior abdominal wall so they can be retrieved later for
the neobladder-urethral anastomosis.
We prefer to use 60 cm of distal ileum beginning 15 cm
proximal to the ileocecal junction for the formation of the
neobladder. Sigmoid colon can alternatively be used ifadequate small bowel is lacking. The desired ileal segment
is identified and then marked distally with two red vessel
loops and proximally with two blue vessel loops (one at
50 cm and one at 60 cm) placed through the mesentery. We
prefer this to marking with a suture as it provides better
ability to manipulate the bowel with less trauma. The
length of the ileal segment may be approximated using a
sterile flexible tape measure, premeasured silk suture, or
open-ended ureteral catheter.
The ileum is then transected distally with a 60-mm
laparoscopic stapler via the left-sided assistant AirSeal
port and a blue stapler load (3.5-mm thickness). We have
previously reported on our experience with IV injection of
2 mL of 2.5 mg/mL indocyanine green for identification of
mesenteric vessels [17]. This may be a useful adjunct for
the urologist, particularly when first starting out. We
continue dividing the mesentery in this plane using an
additional white vascular stapler load (2.5-mm thickness)
to allow for proper mobilization of the neobladder.
At this point, we do place a dyed 3-0 Vicryl suture at the
distal bowel segment near the red vessel loops. Using an
undyed 3-0 Vicryl, the ileal segment is marked at approxi-
mately 25 cm and again at 50 cm from the distal end. These
sutures represent the apex of the posterior plate and
beginning of the afferent limb, respectively. The proximal
end of the ileal segment is then divided, again using a blue
stapler load. Another purple-dyed 3-0 Vicryl suture is
placed to mark the proximally transected ileum.
In restoring bowel continuity, the previously placed
vessel loops are very useful for identification, orientation,
and manipulation of the ileum. The anastomotic bowel
segments are brought adjacent to one another using the
vessel loops in order to achieve a side-to-side, functional
end-to-end ileoileal anastomosis. We again employ the
60-mm laparoscopic tissue stapler to deploy two loads on
the adjacent antimesenteric ileal walls in series. The open
ends of ileum are closed with a tissue stapler load deployed
transversely, mirroring the open technique. It is imperative
to perform the ileoileal anastomosis above the excluded
segment so that the neobladder can be formed below the
mesentery and easily translocate into the pelvis.
The undyed marking suture at 25 cm (site of urethral
anastomosis) is grasped by the fourth robotic arm and
retracted into the pelvis. This aligns two 25-cm ileal seg-
ments adjacent to each other. The additional 10 cm of
ileum is used for the afferent limb. Goh et al. [18] prefers
to use 44 cm for the ileal segment and 16 cm for the
afferent limb, but ultimately this decision is based on sur-
geon preference. The 50 cm of ileum is then detubularized.
Use of a chest tube or large Foley catheter inserted into the
bowel segment is optional, and may prevent injury to the
back wall of the bowel.
Several 2-0 absorbable interrupted sutures are placed at
6e8 cm intervals to appose the edges of the posterior plate
of the neobladder. A final 6 cm tag is placed to facilitate
manipulation during final suturing. A watertight 2-0 barbed
suture (V-loc) then runs the entire length of the posterior
wall along the previously approximated edges.
With the previously placed 3-0 barbed sutures at the 5
and 7 o’clock positions of the urethra, the urethro-
neobladder anastomosis is started after rotating the
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with caudal traction.
The anastomosis is performed in a running fashion with a
barbed suture. Goh and colleagues [18] have described an
alternative approach, using double armed 3-0 Monocryl
suture on an RB-1 needle starting from the 6 o’clock posi-
tion. In experimenting with different ways to perform the
anastomosis, we have found that the use of barbed sutures
provides enhanced technical ability and ensures a water-
tight connection [19]. The posterior portion of the anasto-
mosis is completed over a 22 or 24 Fr Hematuria catheter.
The anastomosis is completed anteriorly using interrupted
sutures or by continuing to run the previous posterior
sutures.
Collins and colleagues [20] perform the urethro-
neobladder anastomosis at the beginning of the proce-
dure, immediately following identification, but prior to
harvest of the ileal segment. This strategy ensures
adequate ileal length and mesenteric mobility so that the
surgeon may be sure to complete the urethro-neobladder
anastomosis under the least tension possible. If there is
difficulty reaching the urethra, the surgeon can shift the
segment of bowel to be harvested to gain additional length.
Each ureter is then spatulated and separately anasto-
mosed to the afferent limb using the Bricker technique with
interrupted or continuous 5-0 monocryl sutures. A Wallace
technique may be employed where desired. Each ureter is
intubated with a completely internalized 6 Fr x 30 cm JJ
ureteral stent prior to completing the ureteral anastomoses
[21]. We typically place these through the left-sided assis-
tant port, though an alternative technique may be used to
introduce 5 Fr stents percutaneously through a 2-mm nee-
dle in the abdominal wall. The angle of entry into the
ureters using this method creates a more favorable angle
for advancing the stents into the renal pelvis.
Neobladder closure is started by cross-folding the pos-
terior plate on itself and fixing the midpoint with a hori-
zontal mattress suture. This aligns the edges for closure and
maintains symmetry of the pouch. The anterior wall of the
neobladder is closed with running 2-0 barbed V-loc suture.
A suprapubic tube (SPT) may be placed into the neobladder
prior to final closure if desired. We prefer SPT placement to
allow for easier irrigation postoperatively. Next, the neo-
bladder is irrigated via the transurethral Foley catheter to
ensure a watertight closure; any leaks can be repaired with
interrupted 2-0 Vicryl sutures. Surgical specimens may be
extracted vaginally in women, or through extension of the
midline camera port incision in men. Vaginal closure and
reconstruction should not be overlooked, as this step has
important implications for postoperative sexual health and
quality of life. A drain is placed in the pelvis through a
lateral port site and put to bulb suction.
All 10 mm or greater port sites are re-approximated
using 1-0 Vicryl suture at the level of the fascia. The Carter-
Thomason method may be used where desired. The fascia
and skin are then closed in the standard fashion.
2.3.2. Intracorporeal ileal conduit
Isolating ileum for an ICIC is achieved in a similar fashion to
the ONB except a smaller length of ileum is harvested
(usually 15 cm). This was first reported by Balaji et al. [22]
and later modified to include the Marionette technique by
Guru and colleagues [23]. The Marionette techniqueincludes placing a long suture into the distal aspect of the
isolated bowel segment and then bringing the suture out
through one of the assistant ports so that the bowel can be
manipulated to provide appropriate exposure for the sur-
geon. After isolating the bowel segment and restoring
bowel continuity with the Endo-GIA stapler through the
15 mm assistant port, the left ureter is delivered under the
sigmoid mesocolon to the right side. A small defect may be
made in the distal aspect of the conduit and irrigated
laparoscopically. Alternatively, irrigation may be per-
formed while maturing the stoma after the robotic is
undocked. Ureteroileal anastomosis and intracorporeal
stent placement is performed similarly to the ONB. Prior to
undocking the robot, full length 3-0 Vicryl suture is then
placed in the distal aspect of the conduit and brought
extracorporeally through the robotic port closest to the IC
site so that it may be readily identified and brought up to
the skin during ostomy creation.3. Choice of urinary diversion
ICUD following RARC may theoretically take many forms.
While IC and ONB are the most commonly performed, there
have been recent reports of continent cutaneous diversion
(Indiana pouch) as well [24]. The urologist is encouraged to
think broadly about the type of diversion offered to each
individual patient. Choice of diversion will ultimately
depend not only on patient preference, but also their
health and functional status. Many patients may be intrin-
sically drawn to ONB, owing to superior cosmetics (ostomy
is not required) and perceived quality of life advantage.
Even here the surgeon has options on the type of neo-
bladder, though a recent 2015 review of RARC with intra-
corporeal neobadder (ICNB) series reported the Studer
pouch as the most commonly performed by far, citing this
form of neobladder in over 96% of reviewed ONB patients
[25]. Indiana pouch is also attractive to patients as it
maintains continence, but intracorporeal descriptions are
limited and this procedure is not widely performed at this
time. Whatever the decision, the urologist must counsel the
patient thoroughly and help them to arrive at the best
possible choice given their specific comorbidities and
functional capabilities.
In order to be considered a candidate for ONB, patients
should not have significant stress urinary incontinence,
should have intact urethral function, and should not have
transitional cell or prostatic carcinoma involving the
bladder neck and/or urethra. These authors recommend
bladder neck or distal urethral frozen sections at the time
of RARC to rule out occult malignancy. ONB also requires
the motor and cognitive abilities necessary to perform
specified voiding behaviors including self clean intermittent
catheterization. Historically, chronic renal insufficiency
with serum creatinine >2 mg/dL (or GFR <40 mL/min/
1.73 m2) is seen as a contraindication to continent diversion
as well. If any of these factors are present, the urologist is
urged to strongly consider a non-continent diversion such as
IC formation. When considering the use of colon in a
continent cutaneous diversion, the urologist should also be
mindful of concomitant comorbidities of the gastrointes-
tinal system, including inflammatory bowel disorders.
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patients undergoing consecutive RARC over a 9-year period
with median follow up of 35 months and suggested higher
complications rates for ONB and cutaneous continent
diversion (Indiana pouch) versus IC, despite a less healthy
IC cohort. Sixty-eight percent of patients received a
continent diversion with a 77% overall and 32% major
complication rate, while most complications were gastro-
intestinal, infectious, of hematologic. In multivariate ana-
lyses, ONB was a predictor for 90-day major complication
rate compared to IC with OR 4.97 (95%CI 1.88e13.2,
p Z 0.001), and both ONB and Indiana pouch had signifi-
cantly higher overall 90-day adverse events. Indiana pouch
in particular was a predictor for blood transfusion with OR
3.55 (95%CI 1.33e9.44, p Z 0.01), and the most common
contributor to complications in the ONB group was urethral
anastomotic leak (24.2%). However, it should be noted that
all diversions were performed extracorporeally in this
series.
Several large series have been published highlighting
single institutional experiences with RARC-ICNB (Table 1) as
well as RARC with ICIC (Table 2). Notably, the report by Goh
et al. [18] in 2012 detailed perioperative outcomes for both
ICNB and ICIC, thus appearing in both accompanying tables
here. They performed eight neobladders and seven ICs and
reported no difference in perioperative outcomes,
including operative time, estimated blood loss (EBL), time
to liquid and regular diet, length of hospital stay, and
oncologic outcomes. It is generally well accepted that the
majority of complications after radical cystectomy are
related to the diversion, rather than the extirpative portion
of the procedure [27]. Thus it stands to reason that aTable 1 Series of RARC with intracoporeal orthotopic ileal neo
Series Patients (n) Operative
time (min)
EBL
(mL)
LOS (d) Clavien Ie
complica
Pruthi et al.,
2010 [55]
3 330 221 5 e
Jonsson et al.,
2011 [56]a
36 480 625 9 36
Goh et al.,
2012 [18]a
8 450 225 8 63
Canda et al.,
2012 [57]
27 594 429 10.5 48
Collins et al.,
2014 [20]a
80 420 475 9 48
Desai et al.,
2014 [29]a
132 456 430 11 46
Schwentner
et al.,
2015 [58]
62 477 385 16.7 24
EBL, estimated blood loss; LOS, length of stay; PSM, positive surgical
a Data sets from these papers may include overlapping patients.primary goal of the urologist should be to answer the
question: which type of diversion, if any, causes the least
severe and fewest numbers of complications? For their
part, Goh et al. [18] did not find any differences in major or
minor complications at both 30- and 90-day follow-up. The
overall complication rate was 73%, but high-grade compli-
cations comprised only 13% of the total cohort. Re-
admission rates were also similar, including seven re-
admissions for minor complications and two for major
complications. It should be stated this study included a
total of only 15 total patients, and thus even a low number
of absolute re-admissions correlates with a relatively large
percentage of the cohort. Larger series of patients for both
neobladder and IC have since been reported.
Desai et al. [28] reported on 18 patients with ICNB vs. 19
patients with ICIC in 2014. All procedures were done
completely intracorporeally without any cases converted to
open. The ICIC cohort was significantly older (75 vs. 62
years) and had higher ASA classification, but did not differ
in Charlson Comorbidity Index, tumor histology, grade,
stage, or rates of neoadjuvant chemotherapy. There was no
significant difference in EBL (250 vs. 200 mL), operative
time (386 vs. 387 min), transfusion rate (32% vs. 17%), time
to ambulation (3 vs. 4 days), time to PO intake (5 vs.
4 days), or length of stay (8 vs. 13 days, pZ 0.078), though
this last parameter may be viewed as clinically significant.
This was followed by the largest series of ICNB published
to date, including 132 consecutively performed RARC-ICNB
at two institutions [29]. Mean operative time was 456 min,
EBL was 430 mL, and mean hospital stay was 11 days. The
overall 30-day complication rate was 47%. An additional 28%
complication rate between 30 and 90 days was noted, butbladder.
II
tions (%)
Clavien IIIeV
complications (%)
PSM rate (%) Continence
outcomes
e e e
36 e 96% daytime
continence
38 0 75% daytime
continence
26 3.7 65% daytime
continence;
17.6% night time
continence
46 1 87% daytime
continence;
80% night time
continence
29 0.8 84% complete
daytime and
night time
continence
26 6.4 88% overall
margin; RARC, robot-assisted radical cystectomy.
Table 2 Series of RARC in intracorporeal ileal conduit.
Series Patients (n) Operative
time
median
(min)
EBL
median (mL)
LOS
median (d)
Clavien IeII
complications (%)
Clavien IIIeV
complications (%)
PSM rate (%)
Jonsson et al.,
2011 [56]
9 460 350 17 22 56 e
Goh et al.,
2012 [18]
7 450 200 9 66 0 0
Azzouni et al.,
2013 [59]
100 352 300 9 66 15 4
Collins et al.,
2013 [20]
43 292 200 9 24 59 11.6
EBL, estimated blood loss; LOS, length of stay; PSM, positive surgical margin; RARC, robot-assisted radical cystectomy.
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plications were limited to 29% overall. The majority of
these were infectious (28.8%) and genitourinary (21.2%).
In a review of 1000 ONB following RC, Hautmann et al.
[27] reported that the majority of complications after RC
are related to diversion part of the procedure. It follows
then that the majority of complications with a completely
intracorporeal approach will also be related to the diver-
sion. Table 3 illustrates diversion-related complications for
the two largest published series of ICUD, one with all ICNB
and the other with all ICIC. We defined diversion-related
complications as those of GU, GI, or infectious etiology.
Overall complication rates were comparable in the ICNB vs.
ICIC series (75% vs. 81%, respectively), but it should be
noted that the ICNB series experienced more late compli-
cations that the ICIC series. Close inspection of the re-
ported data reveals that the main difference is the timing
and incidence of UTI may be responsible for this discrep-
ancy, where ICNB patients seemed to experience higher
rates of late UTI, while ICIC patients experienced more UTIs
early in their post-operative course. The reason for this is
not clear, though may be related to noncompliance with or
improper performance self-catheterization after leaving
the hospital. If true, this highlights the importance of
proper patient selection when considering ONB.
Though most of these listed series are non-randomized
and retrospective, data reporting outcomes on ICNB and
ICIC in a single publication from single institution hold the
distinct advantage of open and direct comparison betweenTable 3 Diversion-related complications of RARC-ICUD.
Series Patients
(n)
Ileal
conduit,
n (%)
Neobladder,
n (%)
Total
complications
(%)
Clav
com
(%)
Azzouni
et al.,
2013 [59]
100 100 (100) 0 (0) Infectious 31
GI 36
GU 11
Other 3
66
Desai
et al.,
2014 [29]
132 0 (0) 132 (100) Infectious 29
GU 21
GI 8
Other 17
46
GI, gastrointestinal; GU, genitourinary; RARC-ICUD: robot-assisted radthe two techniques. It effectively controls for surgeon
experience, volume, perioperative care from ancillary
staff, and regional idiosyncrasies that are otherwise
virtually impossible to capture when comparing separate
cohorts in time and space across the literature. Nonethe-
less, data related to RARC-ICUD remain limited to small
institutional series performed by experienced robotic
surgeons who also have experienced teams. It is not
routinely performed in the community and it is important
to consider this reality while interpreting the available
literature on the subject. At the same time, experienced
surgeons can also perform the described steps of RARC-
ICUD purely laparoscopically, as the steps are by and large
the same.
4. Intracorporeal vs. extracorporeal urinary
diversion
A completely intracorporeal approach to the urinary
diversion is attractive to both the patient and urologist, as
it seeks to preserve the minimally invasive benefits of RARC
in the first place. Less intraoperative blood loss, minimal
fluid shifts and decreased insensible fluid losses, quicker
return of bowel function, and shorter length of stay are all
potential advantages [18]. In females there is the added
opportunity for specimen extraction through the vagina,
which may preclude a mini-laparotomy altogether. In such
cases, incisional morbidity can be all but eliminated.ien IeII
plications
Clavien IIIeV
complications (%)
Early
complications
(<30 days) (%)
Late
complications
(30e90 days) (%)
15 63 18
29 47 28
ical cystectomy with intracorporeal urinary diversion.
162 J.M. Sandberg, A.K. HemalThe International Robotic Cystectomy Consortium (IRCC)
recently published an extensive analysis of perioperative
outcomes in patients undergoing intracorporeal versus
extracorporeal urinary diversion (ECUD) after RARC with at
least 90-day follow-up [30]. The IRCC is a collection of 18
different private and academic international centers that
maintains prospective data on what is now nearly 1000
patients treated with RARC for clinically localized bladder
cancer. One hundred and sixty-seven patients underwent
ICUD (ONB 61; IC 106) while 768 had ECUD (ONB 198; IC
570). Operative times were equivalent (414 min) as were
the 30-day reoperation rates. There was no difference in
90-day complication rates, though the results trended in
favor of ICUD (41% vs. 49%, p Z 0.05). The ICUD group did
have a longer hospital stay by 1 day, which approach sta-
tistical significance (9 vs. 8 days, p Z 0.086). This is
consistent with another recent review comparing ICUD to
ECUD, in which there was not sufficient evidence to
conclude one method was superior to the other in terms of
length of stay, though ICUD trended toward higher number
of hospital days [31]. Significantly, however, rates of
gastrointestinal complications were lower (p  0.001) in
the ICUD group, and they were far less likely to experience
a complication within 90 days (32% reduction) (odds ratio:
0.68; 95% confidence interval (CI), 0.50e0.94; p Z 0.02).
The main disadvantage of the IRCC study was its retro-
spective nature. However, it carries distinct advantages
over smaller single institutional series as it suggests
generalizability of good outcomes across multiple interna-
tional centers and surgeons in the performance of ICUD. It
is also the largest, most thorough comparison between
extracorporeal and intracorporeal diversion to date.5. RARC vs. ORC
Before deciding whether or not to perform a ICUD the
urologist must choose to perform RARC over ORC in the first
place. Beyond data on perioperative outcomes, there are
many factors that contribute to this decision, including
institutional culture, access to necessary equipment and
technology, and properly trained ancillary staff. Desire and
capability of the urologist are chief amongst these factors,
and while the literature suggests an early steep learning
curve, there is also evidence to support improvement in
perioperative measures with increasing experience. This
has direct impact on costs as well, which is seen as a po-
tential barrier to future wide spread adoption of RARC.
Indeed, multiple studies have demonstrated a shorter
learning curve for RARC when compared to robot-assisted
radical prostatectomy, which has been wildly popular
amongst urologists [32e34].
Operative time, EBL, lymph node yield, and margin
positivity were all evaluated in a 2010 analysis of 496 pa-
tients undergoing RARC across 21 surgeons at 14 different
institutions [35]. The authors of this review suggested a
quota of 30 cases to achieve an acceptable level of profi-
ciency in RARC, and that outcomes were further improved
with previous experience with robot-assisted radical pros-
tatectomy. In 2014, Desai et al. [29] reported on significant
improvements between multiple parameters for the first 15
cases vs. numbers 76e86 for a single surgeon. Medianoperative time decreased from 527 to 375 min (p < 0.001),
median EBL decreased from 550 to 200 mL (p < 0.001),
median length of stay decreased from 10 to 7 days
(p Z 0.028), and overall 30e90-day complications trended
toward significant improvement (60% vs. 36%, p Z 0.057).
Independent of approach, RC has been associated with
significant morbidity and post-operative complications.
Multiple series for ORC have reported complications rates in
the range of 40%e70%, including a 13%e40% rate of high-
grade complications [36,37]. As previously shown, RARC is
associated with a similarly high complication rate, whether
the diversion is performed intracorporeally or extracorpo-
really and regardless of type of diversion performed.
However, the vast majority of published series have
demonstrated comparable, and in many cases improved
complications rates over ORC, a strong conclusion drawn in
a recent meta-analysis [38,39]. This review of 962 total
cases across one RCT, eight prospective studies, and four
retrospective studies suggested reduced complications
rates for RARC (p Z 0.04), higher lymph node yield
(p Z 0.009), less EBL (<0.001), lower need for blood
transfusion (p < 0.001), and shorter length of hospital stay
(p < 0.001). Though follow-up was too short across the
studies to establish meaningful oncologic and survival data,
positive surgical margin (PSM) rates as a surrogate for
oncologic control were equivalent between ORC and RARC.
In a more recent meta analysis, there was statistically
significant weight mean differences in operative time
(83.60 min; 95%CI, 57.1e110.1 min; p < 0.00001 in favor of
ORC), blood loss (521 mL; 95%CI, 644 to 399 mL;
p < 0.00001 in favor of RARC), need for transfusion (OR:
0.16; 95%CI, 0.1e0.27; p < 0.00001 in favor of RARC), and
in-hospital stay (WMD: 1.26; 95%CI, 2.08 to 0.43;
p Z 0.003 in favor of RARC), whereas rates for intra-
operative complications (OR: 1.34; 95%CI, 0.37e4.77;
p Z 0.65) were similar for RARC and ORC. Rates for any
grade of complication and for high-grade complications at
90 days favored RARC, whereas all other permutations of
complication data were shown to be equivalent between
RARC and ORC [40]. This represents perhaps some of the
strongest data to support the use of RARC over ORC when
performed at a high volume center by an experienced
surgeon.
Until recently, data have been limited in describing
oncologic outcomes, as the previously mentioned series of
RARC-ICUD have provided only short-term data, often using
surrogates such as PSM and lymph node yield to compare
oncologic outcomes. Collins et al. [41] reported on
medium-term oncologic data on 113 patients undergoing
RARC-ICUD. PSM were reported in 5.3% of patients and a
resulting cancer-specific survival of 81% at 3 years and 67%
at 5 years, which are favorable when compared to open
series. The 2013 meta analysis by Li et al. [39] suggested
RARC is associated with higher lymph node yields and
equivalent PSM rates when compared to ORC, which have
historically ranged from 0 to 6.3% [42,43].
The RARC-ICUD series presented in Tables 1 and 2
demonstrate similar PSM rates to open series, though PSM
rates of 11.6% by Collins et al. is indeed an outlier in this
respect (Table 2). The higher PSM rate in the IC group was
likely due to a higher number of patients with clinical stage
T3/T4 disease preoperatively (13.9% compared to 4.3% for
RARC-ICUD 163the neobladder group). Indeed, patients with higher clinical
T stage translated to higher pathologic T stage, which were
also the majority of patients with PSMs. When the PSM rate
for the IC and neobladder groups are taken as a whole, it
aligns more closely with historically reported figures at
5.3%.
To date, the longest-term data published on oncologic
outcomes for minimally invasive RC demonstrate similar
results to those reported in ORC [43], though it should be
noted that only 17 out of 121 patients in this series un-
derwent RARC while others received either purely laparo-
scopic or laparoscopic-assisted procedures without robotic
assistance. The 10-year cancer-specific survival rate was
63% and overall survival was 35%, which is similar to other
series of ORC [44,45]. The authors admit the introduction of
selection bias in this series as many of the early patients
selected for minimally invasive RC were healthier and had
lower stage disease as they worked to perfect their surgical
technique early on. The largest series of ICNB published by
Desai et al. [29] in 2014 reported 5-year overall, cancer-
specific, and recurrence free survival was 72%, 72%, and
71%, respectively.
Still, the randomized control trial remains the gold
standard for comparing two therapies. Three RCTs
comparing ORC to RARC have been published to date,
though oncologic data are limited. The first, published by
Nix et al. [46] in 2010 randomized 21 patients to RARC and
20 patients to ORC while demonstrating non-inferiority of
lymph node yield as the primary endpoint. As secondary
outcomes, there were no differences in complication rate
or hospital stay. The robotic group enjoyed lower mean EBL
(258 vs. 575 mL, p < 0.0001), shorter time to flatus and
bowel movement (2.3 vs. 3.2 day, p Z 0.0013; 3.2 vs.
4.3 day, pZ 0.0008), and lower narcotic use (pZ 0.0044),
while the open group had a predictably shorter operative
time (4.2 vs. 3.52 h, p < 0.0001). There was no difference
in mean lymph node yield (19 vs. 18 LNs, p Z 0.52) or
positive margins (0), while pathologic stage of the specimen
was also similar. This was followed by a 2013 RCT evaluating
perioperative outcomes and oncologic efficacy in 40 pa-
tients [47]. Again, there was no significant difference in
PSM rates or lymph node yield, and EBL was significantly
lower in the robotic group.
The largest and most recent RCT comparing ORC to RARC
was published in 2015 with primary endpoints including 90-
day Clavien grade II-V complications [48]. Secondary out-
comes were established as comparison of high-grade com-
plications, EBL, operative time, pathologic outcomes, 3-
and 6- month patient-reports quality of life measures, and
costs. The trial randomized 60 patients to RARC and 58
patients to ORC. All patients regardless of randomization
received an open urinary diversion. There were no signifi-
cant differences in 90-day Clavien e complications (62% vs.
66%, p Z 0.7), and the trial was closed early as these re-
sults met interim analysis futility criteria. Not surprisingly,
this trial once again demonstrated decreased EBL and
longer operative times in the robotic group, and similar
rates of PSM and lymph node yields. Mean hospital stay was
also similar at 8 days, with similar quality of life measures
reported at 3 and 6 months. Importantly, analysis was
performed to compare both operating room and total
inpatient costs. A robotic vs. open cystectomy andneobladder was shown to be US$3920 more expensive on
average (US$19,231 vs. US$15,311, p < 0.0001), while the
IC was cheaper overall, but still more expensive when
performed with the robot (US$18 388 vs. US$16 648,
p < 0.05). Ultimately, the authors concluded that RARC
with either IC or neobladder did not confer any benefit to
the patient, while placing increased cost burden on the
health care system.
The publication of this most recent RCT has blurred what
was, until recently, a picture coming into ever-sharper
focus. While the authors should be commended for con-
ducting the largest RCT representing the highest level of
evidence published to date, it is important to acknowledge
a significant limitation. All urinary diversions in the RARC
group were performed extracorporeally, which may have
acted to negate the beneficial effects of the minimally
invasive approach. Indeed a recent meta-analysis (dis-
cussed earlier), reported a 32% reduction in perioperative
complications when performing the urinary diversion
intracorporeally compared to extracorporeally [30]. None-
theless, this trial did not demonstrate definitive advantage
for RARC over ORC. While RARC did appear equivalent to
ORC in many respects, it did so at a higher inpatient care
cost primarily owing to longer operative times, increased
equipment costs, and no benefit in length of stay.
Many studies assessing the feasibility of RARC have been
wrought with selection bias, particularly in the earliest
series. Patients have historically been excluded from RARC
if they are morbidly obese, have other significant comor-
bidities (e.g., severe cardiovascular or pulmonary disease),
or have large, bulky or extravesical disease, which may lead
to better outcomes for RARC cohorts due to more favorable
baseline characteristics rather than surgical technique.
Indeed early series comparing ORC to RARC demonstrated a
selection bias toward less-advanced disease in robotic co-
horts [49,50]. In addition, patients with a history of pelvic
radiation are often excluded from participation in surgical
series, and thus published results may not be generalizable
to patients with similar history in real-life practice. Novice
surgeons tend to select patients by strict criteria. However,
as surgeon experience grows, increasingly difficult and
complicated cases may be attempted.
Absolute contraindications to RARC include patient
inability to tolerate the physiologic stress of surgery to
begin with, large body habitus, and multiple previous
abdominal surgeries, which may preclude safe laparoscopic
access. Those with severe cardiopulmonary disease may be
difficult to ventilate while the abdomen is fully insufflated
in the steep Trendelenburg position, placing them at
increased risk for hypercarbia. Other relative contraindi-
cations may include previous extensive abdominal surgery,
bleeding diatheses, severe cardiac disease, or Jehovah’s
Witnesses. As experience increases, the individual surgeon
may feel increasingly comfortable offering RARC to an
increasingly comorbid population.
6. Health-related quality of life (HRQoL) and
functional outcomes
Table 1 reports the published data regarding continence
outcomes in patients following ICNB at times greater than
164 J.M. Sandberg, A.K. Hemal30 days after surgery, many of which extend to 12 months.
Daytime continence rates range from 65% to 96% in these
series, but this also highlights the need to counsel patients
appropriately on the possibility of some level of leakage
post operatively. Nighttime continence tends to be lower,
likely owning to positional effects of sleeping. Unfortu-
nately, there are very limited HRQoL data directly
comparing different types of urinary diversion, including
those influenced by the choice between intra- or extra-
corporeal diversion.
Patients in multiple series universally experience
decreased HRQoL score immediately following the opera-
tion, but these consistently rebound with time. One study
was able to use the Functional Assessment of Cancer
Therapy-Bladder (FACT-BL) questionnaire to assess pa-
tients’ attitudes following RARC-ECUD [51]. They reported
a return to baseline in HRQoL parameters in about 3 months
and in many patients HRQoL actually exceeded pre-
cystectomy levels, which is a useful benchmark in preop-
erative counseling of patients considering RARC. Poch et al.
[52] used the Bladder Cancer Index to assess urinary and
bowel functional scores, and noted those undergoing ICUD
returned to baseline sooner than those in the ECUD group.
Overall, both urinary and bowel domain scores returned to
baseline by 6 months, while sexual function did not
normalize until 18e24 months. Importantly, multiple series
have demonstrated continued improved continence rates at
12 months compared to 6 months post-surgery, thus it is
imperative to counsel patients that HRQoL may continue to
improve with time.
Tyritzis et al. [53] reported on 70 patients undergoing
RARC-ICNB, and reported 81% of patients undergoing nerve-
sparing RARC were potent at 12 months with or without
phosphodiesterase type 5 inhibitors, while 67% of women
had returned to sexual activity by that time as well. When
performing RARC on a woman and extracting the specimen
vaginally, it is important to consider proper reconstruction
of the vagina, as sexual QoL will be determined by not only
the ability to have intercourse, but also preventing
dyspareunia.
The authors of the most recent EUA guidelines on
muscle-invasive and metastatic bladder cancer noted that
in most patient groups studied, the overall HRQoL after
cystectomy remains good, irrespective of the type of uri-
nary diversion used. The suggestion that continent di-
versions are associated with a higher HRQoL has not been
sufficiently substantiated. It is also important to realize
that QoL will also significantly be determined by the pa-
tient’s personality, coping style, and social support [1].7. Conclusion
The majority of currently published series on RARC report
better outcomes with regard to perioperative parameters,
functional ability, QoL, and complications when compared
to an open operation. Remarkable progress has been made
in the technique and performance of this operation, and
also there is mounting evidence to also support its use as a
safe, reproducible, and oncologically responsible treat-
ment for muscle invasive and other high-risk bladder can-
cers. While ICUD may increase total operative times andcosts, there is also reason to believe that it holds advan-
tages over an extracorporeal approach in perioperative and
early post operative domains.
Still, there are no absolute currently available data to
suggest the superiority of ICUD over ECUD. Surgeons differ
in ability, and thus ICUD should likely be attempted only
after the team has mastered the extirpative portion of the
operation. The lack of quality long-term randomized con-
trol trials continues to make a universal assessment diffi-
cult, and the long-term adoption of RARC will likely depend
on economics as much as patient outcomes. Ultimately,
engineered bladder substitutes may provide a future solu-
tion [54], but until that time urologists must continue to
research and define the best options for our patients.
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